AMS Advanced Medical Solutions Group Plc

TIDMAMS

RNS Number : 2066V

Advanced Medical Solutions Grp PLC

29 November 2019

29 November 2019

Advanced Medical Solutions Group plc

("AMS" or the "Group")

Total Voting Rights

In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 29 November 2019 comprises 214,801,378 ordinary shares of 5p each with voting rights. There are no shares held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

   -     Ends - 

For further information, please visit www.admedsol.com or contact:

 
 Advanced Medical Solutions Group plc                Tel: +44 (0) 1606 
                                                                545508 
 Chris Meredith, Chief Executive Officer 
  Eddie Johnson, Chief Financial Officer 
 
 Consilium Strategic Communications               Tel: +44 (0) 20 3709 
                                                                  5700 
 Mary-Jane Elliott / Matthew Neal / Nicholas   AMS@consilium-comms.com 
  Brown / Olivia Manser 
 
 Investec Bank PLC (NOMAD & Broker)               Tel: +44 (0) 20 7597 
                                                                  5970 
 Daniel Adams / Patrick Robb / Gary Clarence 
 

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand(R) , RESORBA(R) , and LiquiBandFix8(R) . AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal(R) brand as well as under white label. In 2019, the Group acquired Sealantis, an Israeli-based medical device company with a patent-protected internal sealant technology platform.

AMS's products, manufactured in the UK, the Netherlands, Germany, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK and Germany, as well as the recently acquired R&D facility in Israel. Established in 1991, the Group has approximately 650 employees. For more information please see www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVREASFNAESNFFF

(END) Dow Jones Newswires

November 29, 2019 10:08 ET (15:08 GMT)

Grafico Azioni Advanced Medical Solutions (LSE:AMS)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Advanced Medical Solutions (LSE:AMS)
Storico
Da Apr 2023 a Apr 2024